HomeEverythingEducation
Equities & FundsCrypto & Digital AssetsAI & TechnologyBusiness & CorporateUS Politics & PolicyGeopolitics & Global RiskMacro, Rates & FXCommodities & EnergyEuropean Politics & MarketsAsia-PacificReal Estate & Property
Story archiveAll categories
← All Stories

Wegovy maintains lead in GLP-1 weight loss market

Created at 7 Jun · 11:42 PM2 sources
IN SHORT

Wegovy continues to dominate the GLP-1 pill market for weight loss in the US, maintaining its position as a top choice for consumers despite the launch of competitor Foundayo by Eli Lilly.

✉Newsletter

PiQ Daily

Pick your topics. Get only what matters, on your cadence.

Who's Involved

Wegovy
leading GLP-1 pill for weight loss
Foundayo
Eli Lilly's GLP-1 pill
Eli Lilly
pharmaceutical company that launched Foundayo

↳ Why This Matters

Wegovy's continued market leadership highlights its strong position in the growing weight loss drug sector, impacting pharmaceutical company revenues and competitive dynamics.

Key facts

  • Wegovy remains the leading GLP-1 pill for weight loss in the US.
  • Foundayo, a competing GLP-1 pill from Eli Lilly, has been launched.
  • Wegovy continues to be a preferred choice for Americans seeking weight loss treatments.

Wegovy continues to hold its position as the leading GLP-1 pill in the market for weight loss treatments in the United States. This sustained dominance comes even after the introduction of Foundayo, a competing GLP-1 pill developed by Eli Lilly. Despite the new entrant, Wegovy remains a top choice for Americans seeking to lose weight.

Frequently asked questions

Wegovy is a GLP-1 pill used for weight loss.

Foundayo is made by Eli Lilly.

Yes, Wegovy remains a top choice for Americans trying to lose weight.

Get the newsletter.

Pick the topics you actually care about. We'll email when there's news worth your time, on the cadence you choose. Cancel any time from your account.

Cadence
CME Headlines
  • New Product Summary: Initial Listing of Fifty-Five (55) Single Stock Futures Contracts — Effective July 27, 2026
    27 Jul · 4:32 PM
  • New Product Summary: Initial Listing of Twenty-Two (22) Micro Single Stock Futures Contracts - Effective July 27, 2026
    27 Jul · 4:11 PM
  • Initial Listing of Additional Event Contract Swaps on Pro Golf Tournaments
    9 Jul · 9:41 AM

How It Developed

7 Jun · 11:40 PM
The Wegovy pill continues to lead the GLP-1 pill market for weight loss in the US, despite the introduction of Eli Lilly's Foundayo.
MarketWatch

Sources

T1
The Wegovy pill is still dominating the GLP-1 pill marketmarketwatch.com

Related Stories

AI and SpaceX Wealth Fuels New Luxury Spending Habits
8 Jul · 10:06 AM
Levi Strauss raises annual outlook on steady denim demand
8 Jul · 8:17 PM
SK Hynix $28B ADR bookbuild closes Wednesday amid strong demand
8 Jul · 7:57 AM
Memory Stocks Plunge as Year's Hottest Trade Unravels
8 Jul · 2:35 PM
Zhipu AI Shares Rise After Lockup Expiry Amid Investor Support
8 Jul · 8:25 PM